132results about "Carbon-sulfur lyases" patented technology

A substantially purified substance having the properties of a bacterial microcin methionine analog, methionine synthesis inhibitor, tRNA-methionine synthase inhibitors or methionine competitive inhibitor capable of inhibiting tumor cell growth without inhibiting the growth of normal cells or treating neoplastic diseases, and may be used alone or in combination with other anti-cancer agents. The purified substance may also have anti-hyperhomocysteineuria and/or anti-infective properties, such as antifungal activity. The purified substance can be safely administered to animals including humans for the treatment of neoplastic, hyperhomocysteinemia and/or infectious diseases for the treatment of those diseases.

Methods and composition related to the engineering of a novel protein with methionine-γ-lyase enzyme activity are described. For example, in certain aspects there may be disclosed a modified cystathionine-γ-lyase (CGL) comprising one or more amino acid substitutions and capable of degrading methionine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with methionine depletion using the disclosed proteins or nucleic acids.

The present invention is directed to an improved method of treating cystinuria, utilizing the catalytic ability of cystinase to increase the rate of cystine stone dissolution.

Methods and compositions related to the engineering of a protein with L-cyst(e)ine degrading enzyme activity are described. For example, in certain aspects there may be disclosed a modified cystathionine-γ-lyase comprising one or more amino acid substitutions and capable of degrading L-cyst(e)ine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with L-cyst(e)ine using the disclosed proteins or nucleic acids.

The invention relates to a novel high-activity allinase and a preparation method thereof. The preparation method is characterized in that a wild type allinase gene from a garlic bulb is transformed by utilizing a random mutation technology, and a high-activity allinase mutant gene, namely a novel high-activity allinase gene, is obtained; then the novel high-activity allinase gene is expressed in a bacillus subtilis expression system and pichia pastoris expression systems (including a pichia pastoris free expression system and a pichia pastoris cell surface display system) respectively, and recombination strains for producing the high-activity allinase are obtained; detections carried out after fermentation expression show that the specific enzyme activity of the novel high-activity allinase is improved by 50% in comparison with a wild type allinase.

The invention belongs to the field of deep processing of garlic, and particularly discloses a method for purifying alliinase by double-water-phase separation. The method comprises the following steps: (1) peeling and precooling garlic squamous bulbs, immersing in a precooled extract, homogenizing, centrifuging, and discarding garlic slag, thereby obtaining the supernate crude enzyme solution; (2) dissolving ammonium sulfate, sodium dihydrogen phosphate or trisodium citrate in a Britton-Robinson buffer solution, oscillating to completely dissolve, adding a PEG (polyethylene glycol) solution, evenly mixing by oscillation, and standing for phase splitting, thereby obtaining a double-water-phase extractant; (3) adding the crude enzyme solution into the double-water-phase extractant, oscillating, centrifuging, and standing for phase splitting; and (4) ultrafiltering the lower phase of the enriched alliinase, and carrying out vacuum freeze drying on the trapped fluid to obtain the alliinase solid. The method is simple to operate, has the advantages of simple apparatuses, time saving, low cost, and higher alliinase purification multiple and enzyme activity recovery rate than the prior art, and can easily implement scale-up production.

The current invention discloses a genetically engineered bacterium used for the treatment of breast cancer. The said bacterium is attenuated Salmonella typhimurium VNP20009 with cloned L-methioninase gene. The method for constructing this genetically engineered bacterium and the application thereof are also disclosed herein. In the current invention, our biologic drug for the treatment of breast cancer is a type of safe, non-toxic new drug with anti-tumor activity. It can highly express methioninase through recombinant DNA technology using attenuated Salmonella typhimurium VNP20009 as a carrier, which has a strong anti-tumor activity and can meet the needs. The preparation method is simple and easy to operate, showing good application prospect.

The purpose of the present invention is to provide a method for producing selenoneine that allows production of selenoneine at higher yields as compared with a conventional technology, and, therefore, enables selenoneine production on an industrial scale. This purpose can be achieved by a method for producing selenoneine, comprising the step of applying histidine and a selenium compound to a transformant that has a gene encoding an enzyme of (1) below introduced therein and that can overexpress the introduced gene, to obtain selenoneine.

• (1) An enzyme that catalyzes a reaction in which hercynylselenocysteine is produced from histidine and selenocysteine in the presence of S-adenosylmethionine and iron (II).

The invention discloses application of genes Gfegt1 and Gfegt2 of ergothioneine of grifola frondosa to synthesis of the ergothioneine, and belongs to the field of biosynthetic biology. The possible ergothioneine synthetase genes Gfegt1 and Gfegt2 in the grifola frondosa are found out through a homologous comparison method, and RNA of the grifola frondosa is extracted and then subjected to reversetranscription to generate cDNA for cloning obtaining. Carriers for expression, started by utilizing yeast promoters, of the two genes Gfegt1 and Gfegt2 are constructed, and converted into saccharomyces cerevisiae EC1118, then the saccharomyces cerevisiae is absorbed by adding a substrate, reaction and catalysis are conducted in vivo for synthesizing the ergothioneine, after extracting, generationof ergothioneine products is detected through high performance liquid chromatography (HPLC), in-vivo biosynthesis of the ergothioneine is achieved. A brand new biosynthetic pathway is provided for production of the ergothioneine.

Novel semiconductor nanoparticles and methods of biosynthesizing the same are provided by biosynthetic processes using cell-free supernatants and isolated enzymes.

The present disclosure relates to erythroid cells that have been engineered to express a homocysteine reducing polypeptide, or a variant thereof, or a homocysteine degrading polypeptide, or a variant thereof. The engineered erythroid cells may further comprise an amino acid transporter, for example a homocysteine transporter or a serine transporter, or a cystathionine degrading polypeptide. The engineered erythroid cells of the present disclosure are useful in reducing the level of homocysteine in a subject. The engineered erythroid cells of the present disclosure are further useful in methods of treating homocystinuria.

The invention relates to the use of enzymes, nanorods, and nanoelectronic devices to detect cysteine level in a patient sample and relates to the use of the detected cysteine level to predict cancer recurrence in the patient and to prescribe and/or administer an appropriate therapy to a subject. The invention is directed to systems and methods of detecting cysteine level in a sample from a subject, wherein the systems or methods can further comprise measuring at least one additional parameter, such as PSA level, Gleason score and clinical stage. The invention is directed to systems and methods of predicting the probability of a recurrence of a cancer in a subject, wherein the systems or methods can further comprise measuring at least one additional parameter, such as PSA level, Gleason score and clinical stage. The invention further comprises prescribing and/or administering an appropriate therapy to a subject based on the predicted probability of recurrence.

The invention discloses an application of an attenuated salmonella typhimurium genetic engineering bacterium in preparation of a drug for treating liver cancer; the bacterium is attenuated salmonella typhimurium VNP20009 cloned with an L-methioninase gene; the attenuated salmonella typhimurium with a plasmid cloned with the L-methioninase gene can continuously express L-methioninase in a liver cancer tumor tissue, a lot of methionine and other nutrient substances are consumed, and tumor cells are lack of nutrition and grow slow. The invention also discloses a construction method and an application of the genetic engineering bacterium. A biological drug for treating liver cancer is a novel safe and toxic-free biological drug having antitumor activity, takes the attenuated salmonella typhimurium VNP20009 as a vector, highly expresses the methioninase by a gene recombination technology, has strong anti-liver cancer tumor activity, and can meet the use demand. The preparation method is simple and easy to operate, and has a good application prospect.

Methods and compositions relating to the engineering of an improved protein with homocyst(e)inase enzyme activity are described. For example, there are disclosed modified cystathionine-γ-lyase (CGL) enzymes comprising one or more amino acid substitutions and capable of degrading homocyst(e)ine. Furthermore, provided are compositions and methods for the treatment of homocystinuria or hyperhomocysteinemia with homocyst(e)ine depletion using the disclosed enzymes or nucleic acids.

The invention discloses a recombinant host cell capable of biosynthesizing cannabinoid phenolic acid, a construction method of the recombinant host cell and a method for biosynthesizing the cannabinoid phenolic acid through the recombinant host cell, and belongs to the field of biotechnology and medicine. The saccharomyces cerevisiae is used as a host, firstly, cannabinoid synthase and cannabinoid phenolic acid synthase are over-expressed in the host, then a metabolic pathway for synthesizing a precursor compound oleylic acid of cannabinoid phenolic acid by using saccharides is constructed in the host, and a metabolic pathway from caproic acid to oleylic acid is further constructed in the host; finally, an endogenous mevalonic acid pathway of a host and a metabolic pathway of acetyl coenzyme A are optimized, the recombinant saccharomyces cerevisiae capable of biologically synthesizing cannabinoid phenolic acid is obtained, a new pathway for producing cannabinoid phenolic acid with high additional value from a cheap carbon source is provided, the production efficiency is high, the period is short, the cost is low, and large-scale production of cannabinoid phenolic acid is facilitated.

In some aspects of the design, novel forms of geranylpyrophosphate:olivetolate geranyltransferase; of olivetol synthase or of geranyl pyrophosphate synthase; of geranylgeranyl pyrophosphate synthase; of olivetolic acid cyclase; and/or of olivetolic acid synthase for making large scale amounts of cannabinoids in cells, in vitro are presented.

The invention belongs to the technical field of genetically engineered drugs and particularly relates to new application of a genetically engineered bacterium VNP20009-M to preparation of a medicine for treating sarcomas. On the current basis, the genetically engineered bacterium VNP20009-M is used for treating the sarcomas, can effectively kill tumor cells to eliminate tumor lesions, and the genetically engineered bacterium has no obvious toxic or side effects on a human body, and therefore, provides a safe and effective new way for treating the sarcomas.

The invention is related to a new method for treating liquid and solid cancers, in a mammal, including human, wherein methioninase is administered before asparaginase. The invention also encompasses the use of a dietary methionine deprivation, possibly combined with methioninase administration, in advance of asparaginase treatment. Methioninase and asparaginase may be used in particular under free form, pegylated form or encapsulated into erythrocytes.